T3 Companies’s Arbutus Biopharma ABUS Stock Holding History

T3 Companies’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-34,000	Closed	-$164K	–	162
2025 Q4	$164K	Buy	+34,000	New	+$153K	0.2%	95

Other funds holding ABUS

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

T3 Companies's ABUS Position: Q1 2026 in Review

T3 Companies sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 34,000 shares — an estimated $164K sold.

T3 Companies first reported a position in ABUS in Q4 2025 and held it in 1 quarter. The position peaked at $164K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

T3 Companies reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
T3 Companies sold 34,000 Arbutus Biopharma shares in Q1 2026, an estimated $164K.
T3 Companies first reported a position in Arbutus Biopharma in Q4 2025 and held it in 1 quarter.
T3 Companies's Arbutus Biopharma position peaked at $164K in Q4 2025.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on T3 Companies's 13F filing for Q1 2026, filed 7 May 2026.